Literature DB >> 17133470

Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry.

Raúl J Andrade1, M Isabel Lucena, Neil Kaplowitz, Beatriz García-Muņoz, Yolanda Borraz, Ketevan Pachkoria, Miren García-Cortés, M Carmen Fernández, Gloria Pelaez, Luis Rodrigo, José A Durán, Joan Costa, Ramón Planas, Anabel Barriocanal, Carlos Guarner, Manuel Romero-Gomez, Teresa Muņoz-Yagüe, Javier Salmerón, Ramón Hidalgo.   

Abstract

A chronic adverse reaction may occur in some instances of drug-induced liver injury (DILI), even despite drug cessation. In our study, we obtained records from a Spanish registry and evaluated cases of DILI with biochemical evidence of long-term damage. Chronic outcome was defined as a persistent biochemical abnormality of hepatocellular pattern of damage more than 3 months after drug withdrawal or more than 6 months after cholestatic/mixed damage. Data on 28 patients with a chronic clinical evolution (mean follow-up 20 months) between November 1995 and October 2005 were retrieved (18 female; overall mean age 55 yr) and accounted for 5.7% of total idiosyncratic DILI cases (n = 493) submitted to the registry. The main drug classes were cardiovascular and central nervous system (28.5% and 25%, respectively), which, in contrast, represented only 9.8% and 13%, respectively, of all DILI cases. The most frequent causative drugs were amoxicillin-clavulanate (4 of 69 cases), bentazepam (3 of 7 cases), atorvastatin (2 of 7 cases), and captopril (2 of 5 cases). Patients with cholestatic/mixed injury (18 of 194 cases [9%]) were more prone to chronicity than patients with hepatocellular injury (10 of 240 cases; P < .031). In the case of chronic hepatocellular injury, 3 patients progressed to cirrhosis and 2 to chronic hepatitis. In the cholestatic/mixed group, liver biopsy indicated cirrhosis in 1 patient and ductal lesions in 3 patients. In conclusion, cholestatic/mixed type of damage is more prone to become chronic while, in the hepatocellular pattern, the severity is greater. Cardiovascular and central nervous system drugs are the main groups leading to chronic liver damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17133470     DOI: 10.1002/hep.21424

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  70 in total

1.  Response to Collyer et al.

Authors:  Robert J Fontana
Journal:  Am J Gastroenterol       Date:  2016-02       Impact factor: 10.864

2.  Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.

Authors:  Robert J Fontana; Paul H Hayashi; Jiezhun Gu; K Rajender Reddy; Huiman Barnhart; Paul B Watkins; Jose Serrano; William M Lee; Naga Chalasani; Andrew Stolz; Timothy Davern; Jayant A Talwakar
Journal:  Gastroenterology       Date:  2014-03-27       Impact factor: 22.682

Review 3.  Idiosyncratic drug-induced liver injury: a clinical update.

Authors:  Haripriya Maddur; Naga Chalasani
Journal:  Curr Gastroenterol Rep       Date:  2011-02

4.  Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law.

Authors:  Xin Shen; Zheng'an Yuan; Jian Mei; Zurong Zhang; Juntao Guo; Zheyuan Wu; Jie Wu; Haihua Zhang; Jieping Pan; Wenming Huang; Huili Gong; Dong Yuan; Ping Xiao; Yanqin Wang; Yi Shuai; Senlin Lin; Qichao Pan; Tong Zhou; Paul B Watkins; Fan Wu
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

5.  Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies.

Authors:  Aileen Smith; John Dillon
Journal:  BMJ Case Rep       Date:  2009-09-02

6.  Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.

Authors:  Harshad Devarbhavi; Guruprasad Aithal; Sombat Treeprasertsuk; Hajime Takikawa; Yimin Mao; Saggere M Shasthry; Saeed Hamid; Soek Siam Tan; Cyriac Abby Philips; Jacob George; Wasim Jafri; Shiv K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

7.  Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.

Authors:  Ayako Suzuki; Raul J Andrade; Einar Bjornsson; M Isabel Lucena; William M Lee; Nancy A Yuen; Christine M Hunt; James W Freston
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

8.  Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.

Authors:  M Isabel Lucena; Mariam Molokhia; Yufeng Shen; Thomas J Urban; Guruprasad P Aithal; Raúl J Andrade; Christopher P Day; Francisco Ruiz-Cabello; Peter T Donaldson; Camilla Stephens; Munir Pirmohamed; Manuel Romero-Gomez; Jose Maria Navarro; Robert J Fontana; Michael Miller; Max Groome; Emmanuelle Bondon-Guitton; Anita Conforti; Bruno H C Stricker; Alfonso Carvajal; Luisa Ibanez; Qun-Ying Yue; Michel Eichelbaum; Aris Floratos; Itsik Pe'er; Mark J Daly; David B Goldstein; John F Dillon; Matthew R Nelson; Paul B Watkins; Ann K Daly
Journal:  Gastroenterology       Date:  2011-04-12       Impact factor: 22.682

Review 9.  Practical guidelines for diagnosis and early management of drug-induced liver injury.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

Review 10.  Current concepts of mechanisms in drug-induced hepatotoxicity.

Authors:  Stefan Russmann; Gerd A Kullak-Ublick; Ignazio Grattagliano
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.